Iambic Therapeutics
Category: AI in Healthcare
AI-driven platform for discovering and developing novel therapeutics, focusing on oncology targets like HER2 and cell-cycle kinases. Iambic Therapeutics was founded in 2019. The company is led by Thomas Miller. Based in San Diego, United States. Team size: 90-119. Total funding raised: $306M. Latest round: Series C. Key investors include ["NVIDIA","Sequoia Capital","Abingworth","Illumina Ventures","Qatar Investment Authority","Alexandria Venture Investments","Mubadala Capital"].
- Founded
- 2019
- Headquarters
- San Diego, United States
- Team size
- 90-119
- Total funding
- $306M
Value proposition
Accelerates drug discovery using physics-based AI and experimental platforms, enabling rapid design and optimization of therapeutics with improved selectivity and brain penetration.
Products and solutions
["IAM-H1 (HER2 inhibitor)","IAM-C1 (CDK2/4 inhibitor)","IAM1363 (Phase 1/1b HER2 inhibitor)"]
Unique value
Integration of physics-informed AI algorithms with automated experimental platforms for weekly design-make-test cycles.
Target customer
Pharmaceutical companies and patients with unmet medical needs in oncology, particularly HER2-positive cancers and cell-cycle driven cancers.
Industries served
["Oncology","Biotechnology","Pharmaceuticals"]
Technology advantage
Proprietary AI models for predicting protein-ligand interactions and optimizing therapeutic candidates, combined with high-throughput synthesis and testing capabilities.
How they differentiate
Iambic leverages physics-based AI platforms for drug discovery, focusing on AI-discovered therapeutics candidates and proprietary tools like Enchant for high-confidence predictions in data-poor scenarios.
Main competitors
["Moderna","Jazz Pharmaceuticals","Advanced Accelerator Applications"]
Key partnerships
["NVIDIA (AI platform collaboration)","Jazz Pharmaceuticals (clinical collaboration)","Lundbeck (brain health therapeutics)","Revolution Medicines ($25M RAS-targeting collaboration)"]
Notable customers
["Revolution Medicines (collaboration partner)","Jazz Pharmaceuticals (clinical collaboration)"]
Major milestones
["Raised over $306M in total funding (including $100M+ Series C in 2025)","Launched Enchant platform for AI-driven drug discovery","First AI-discovered candidate (IAM1363) entered clinical trials","Strategic collaboration with Revolution Medicines worth up to $25M","Featured in CNBC Disruptor 50 (2025)"]
Growth metrics
Clinical-stage with AI-discovered candidates in trials (e.g., IAM1363 in oncology); partnered with Revolution Medicines for AI-driven drug development.
Market positioning
Positioned as an AI-driven therapeutics innovator targeting oncology and other complex disease areas, emphasizing rapid development of differentiated treatments.
Geographic focus
Primarily North America, with operations in San Diego, and expanding partnerships globally.
Patents and IP
7+ patents filed (as of 2025), focusing on AI-driven drug design methodologies and novel molecular structures.
About Thomas Miller
Former Professor of Chemistry at Caltech (2008-2013), PhD in Theoretical Chemistry from University of Oxford (2002-2005), scientist and entrepreneur focused on the nexus of AI, chemistry, and biology, co-founder of Iambic Therapeutics (2019-present), published 130+ peer-reviewed articles and patents
Official website: https://www.iambic.ai